Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...
Ryan Kohlbrenner, MD, interventional radiologist at the UCSF Department of Radiology & Biomedical Imaging, is leading a new ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will ...
– Presentations reinforce the safety, efficacy and durability of the TULSA procedure, further supporting its potential as a mainstream, whole gland or focal treatment for prostate disease – – FARP ...
Ram A. Pathak, M.D., Associate Professor in the Department of Urology at Mayo Clinic in Florida, will give a presentation titled "Multicenter registry of MRI-guided transurethral ultrasound ablation ...
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative ...
Profound also announced that it is launching an initiative to explore the potential of integrating PSMA PET molecular imaging technologies with the TULSA Procedure to support intention-to-treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results